Patents by Inventor Helene Faure

Helene Faure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9073835
    Abstract: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: July 7, 2015
    Assignees: Centre National De La Recherche Scientifique, Universite De Strasbourg
    Inventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Angèle Schoenfelder, André Mann, Maurizio Taddei, Antonio Solinas, Fabrizio Manetti
  • Patent number: 9061997
    Abstract: The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: June 23, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Martial Ruat, Hélène Faure, Tatiana Gorojankina, André Mann, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
  • Patent number: 8981149
    Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: March 17, 2015
    Assignees: Centre National de la Recherche Scientifique, Universite de Strasbourg
    Inventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
  • Patent number: 8957091
    Abstract: The present invention relates to the use of quinolinone derivatives of general formula (I), ligands of the Smo receptor or of related receptors which target a binding site of the receptor which is different from the known ligand binding sites, as research tools for identifying modulators of the Smo receptor or of related receptors, characterizing the Hedgehog signalling pathway and diagnosis; the invention also relates to kits containing said derivatives of general formula (I).
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 17, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Martial Ruat, Helene Faure, Tatiana Gorojankina
  • Patent number: 8889678
    Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: November 18, 2014
    Assignees: Centre National de la Recherche Scientifique, Universite de Strasbourg
    Inventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
  • Publication number: 20140228441
    Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).
    Type: Application
    Filed: September 21, 2012
    Publication date: August 14, 2014
    Applicants: Centre National De La Recherche Scientifique, Universite De Strasbourg
    Inventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
  • Patent number: 8703752
    Abstract: The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate (activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving a tissue dysfunction linked to deregulation of said pathway.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: April 22, 2014
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Martial Ruat, Elisabeth Traiffort, Hélène Faure
  • Publication number: 20130267559
    Abstract: The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.
    Type: Application
    Filed: November 15, 2011
    Publication date: October 10, 2013
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Martial Ruat, Helene Faure, Tatiana Gorojankina, Andre Mann, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
  • Publication number: 20130236912
    Abstract: The present invention relates to the use of quinolinone derivatives of general formula (I), ligands of the Smo receptor or of related receptors which target a binding site of the receptor which is different from the known ligand binding sites, as research tools for identifying modulators of the Smo receptor or of related receptors, characterizing the Hedgehog signalling pathway and diagnosis; the invention also relates to kits containing said derivatives of general formula (I).
    Type: Application
    Filed: November 15, 2011
    Publication date: September 12, 2013
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Martial Ruat, Helene Faure, Tatiana Gorojankina
  • Publication number: 20120196865
    Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.
    Type: Application
    Filed: July 19, 2010
    Publication date: August 2, 2012
    Applicants: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
  • Publication number: 20110275663
    Abstract: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.
    Type: Application
    Filed: April 16, 2009
    Publication date: November 10, 2011
    Inventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Angèle Schoenfelder, André Mann, Maurizio Taddei, Antonio Solinas, Fabrizio Manetti
  • Publication number: 20070060546
    Abstract: The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate(activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving a tissue dysfunction linked to deregulation of said pathway.
    Type: Application
    Filed: January 22, 2004
    Publication date: March 15, 2007
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIF
    Inventors: Martial Ruat, Elisabeth Traiffort, Helene Faure
  • Publication number: 20050192317
    Abstract: The invention concerns diamines of general formula (I), wherein: A represents a group A1 or A2 of general formula (II); B represents a group B1 or B2 of general formula (III); X represents a SO2, CH2, C?O or COO; YZ represents a group of formula CH(R25)—CH(R26) or CH(R27)?(R28), and R1 to R28, identical or different, represent independently of one another, a hydrogen or halogen atom or an alkyl, cycloalkyl, CN, NO2, hydroxy, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, arylalkylamino, diarylamino diarylalkylamino, trihalogenoalkyl or trihalogenoalkoxy group, provided that in the group A1, at least one of the radicals R1, R2, R3, R4 or R5 represents the hydrogen atom when the other four do not represent the hydrogen atom and in the group B1, at least one of the radicals R13, R14, R15, R16 or R17 represents the hydrogen atom when the other four do not represent the hydrogen atom, and their salts with a pharmaceutically acceptable acid, in the form of racemic mixtu
    Type: Application
    Filed: August 7, 2001
    Publication date: September 1, 2005
    Inventors: Philippe Dauban, Robert Dodd, Helene Faure, Martial Ruat, Pierre Potier, Albane Kessler